Vimarsana
Biggest News Aggregation in the World

Page 9 - Radcom News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Radcom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Radcom Today - Breaking & Trending Today

RADCOM (NASDAQ:RDCM) Receives New Coverage from Analysts at StockNews.com - Vimarsana News

RADCOM (NASDAQ:RDCM) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of RADCOM (NASDAQ:RDCM – Free Report) in a research note issued to investors on Friday morning. The firm issued a buy rating on the technology company’s stock. RADCOM Trading Down 0.3 % RADCOM stock opened at $8.66 on Friday. RADCOM has a 12 month low of $8.36 and a 12 […]

Dime Community Bancshares, Inc. (NASDAQ:DCOM) Announces $0.25 Quarterly Dividend - Vimarsana News

Dime Community Bancshares, Inc. (NASDAQ:DCOM) Announces $0.25 Quarterly Dividend

Dime Community Bancshares, Inc. (NASDAQ:DCOM – Get Free Report) declared a quarterly dividend on Thursday, September 28th, Zacks reports. Shareholders of record on Tuesday, October 17th will be paid a dividend of 0.25 per share by the savings and loans company on Tuesday, October 24th. This represents a $1.00 annualized dividend and a yield of […]

Adcom leaves Brainstorm looking at options - Vimarsana News

Adcom leaves Brainstorm looking at options

Brainstorm Cell Therapeutics Inc. said it’s exploring all its options in the wake of a Sept. 27 U.S. FDA advisory committee vote, in which the committee overwhelmingly disagreed with the company that the data it presented supported the effectiveness of Nurown (debamestrocel) for the treatment of mild to moderate amyotrophic lateral sclerosis.

US FDA flexibility the question as Nurown goes before adcom - Vimarsana News

US FDA flexibility the question as Nurown goes before adcom

How flexible should the U.S. FDA evidentiary standards be for a therapy addressing a significant unmet need in a disease such as amyotrophic lateral sclerosis (ALS)? That’s the question the agency’s Cellular, Tissue and Gene Therapies Advisory Committee will ponder Sept. 27 as it looks at the data for Brainstorm Cell Therapuetics Inc.’s Nurown (debamestrocel), a mesenchymal stromal cell therapy targeting ALS.

Head to Head Contrast: Pioneer Bankshares (OTCMKTS:PNBI) and Dime Community Bancshares (NASDAQ:DCOM) - Vimarsana News

Head to Head Contrast: Pioneer Bankshares (OTCMKTS:PNBI) and Dime Community Bancshares (NASDAQ:DCOM)

Dime Community Bancshares (NASDAQ:DCOM – Get Free Report) and Pioneer Bankshares (OTCMKTS:PNBI – Get Free Report) are both small-cap finance companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown […]